We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Welltower
WELL
$165B
| $10.3M | 0.05% |
67,056
+15,732
| +31% | +$2.35M |
|
427
Progress Software
PRGS
$1.71B
| $10.3M | 0.05% |
161,320
+35,270
| +28% | +$2.15M |
|
428
Viatris
VTRS
$20.5B
| $10.3M | 0.05% |
1,151,423
+6,682
| +0.6% | +$56.5K |
|
|
MBX
429
MBX Biosciences
MBX
$3.24B
| $10.3M | 0.05% |
901,103
+23,642
| +3% | +$241K |
|
430
Genmab
GMAB
$17.8B
| $10.2M | 0.05% |
+493,506
| New | +$10.1M |
|
431
BioNTech
BNTX
$23.5B
| $10.2M | 0.05% |
95,498
-22,000
| -19% | -$2.22M |
|
432
Arcturus Therapeutics
ARCT
$171M
| $10.2M | 0.05% |
780,442
| – | – |
|
433
Penske Automotive Group
PAG
$14.3B
| $10.1M | 0.05% |
+58,861
| New | +$9.44M |
|
|
PVLA
434
Palvella Therapeutics
PVLA
$2.14B
| $10M | 0.05% |
445,615
+251,448
| +130% | +$5.9M |
|
|
DVAX
435
DELISTED
Dynavax Technologies
DVAX
| $10M | 0.05% |
1,012,044
-166,719
| -14% | -$1.76M |
|
|
GTLS
436
DELISTED
Chart Industries
GTLS
| $10M | 0.05% |
+60,720
| New | +$8.92M |
|
437
Ultragenyx Pharmaceutical
RARE
$2.53B
| $9.94M | 0.05% |
273,251
+4,789
| +2% | +$173K |
|
438
Duke Energy
DUK
$96.7B
| $9.92M | 0.05% |
84,074
+18,514
| +28% | +$2.18M |
|
|
STKL
439
DELISTED
SunOpta
STKL
| $9.91M | 0.05% |
1,709,033
+205,734
| +14% | +$1.08M |
|
|
SAIL
440
SailPoint Inc
SAIL
$9.72B
| $9.79M | 0.05% |
428,371
| – | – |
|
441
KKR & Co
KKR
$96.2B
| $9.74M | 0.05% |
73,210
+16,178
| +28% | +$1.89M |
|
442
Boeing
BA
$188B
| $9.56M | 0.05% |
45,630
-169,539
| -79% | -$32M |
|
443
McGrath RentCorp
MGRC
$2.96B
| $9.47M | 0.05% |
+81,675
| New | +$9.07M |
|
444
Inhibrx
INBX
$1.25B
| $9.46M | 0.05% |
662,868
+304,432
| +85% | +$3.94M |
|
445
International Paper
IP
$22.4B
| $9.29M | 0.05% |
+198,291
| New | +$9.37M |
|
|
RDUS
446
DELISTED
Radius Recycling
RDUS
| $9.22M | 0.05% |
+310,500
| New | +$9.12M |
|
|
APLS
447
DELISTED
Apellis Pharmaceuticals
APLS
| $9.19M | 0.05% |
530,923
+312,073
| +143% | +$5.78M |
|
448
Cadence Design Systems
CDNS
$94.1B
| $9.1M | 0.05% |
29,535
-83,184
| -74% | -$24.2M |
|
449
ImmunityBio
IBRX
$7.29B
| $9.1M | 0.05% |
3,445,871
+774
| +0% | +$2.08K |
|
450
Stryker
SYK
$128B
| $8.87M | 0.05% |
22,415
+5,976
| +36% | +$2.24M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.